Decoding Resistance: A Spatial Map of Treatment Failure in Gastric Cancer
A landmark study in Gastroenterology has utilized advanced spatial transcriptomic profiling to uncover the complex and heterogeneous mechanisms of acquired resistance to HER2-targeted therapies in gastric cancer. Researchers analyzed over 1500 regions across 30 tumors, including 15 HER2-positive cancers treated sequentially with trastuzumab and trastuzumab deruxtecan (T-DXd). The analysis revealed distinct escape pathways: one-third of patients developed an epithelial-mesenchymal transition (EMT) phenotype linked to immune checkpoint upregulation, another third activated the endoplasmic reticulum-associated degradation (ERAD) pathway, and T-DXd resistance was associated with HLA loss and altered oxidative phosphorylation. This granular, spatially-resolved view of tumor evolution under therapeutic pressure provides a critical roadmap for overcoming drug resistance in oncology.
Study Significance: For nephrology professionals, this research offers a powerful methodological blueprint for investigating complex, treatment-resistant diseases like progressive chronic kidney disease (CKD) or recurrent glomerulonephritis. The application of spatial transcriptomics could map the heterogeneous cellular and molecular landscape within a single kidney biopsy, revealing distinct pathways to fibrosis, inflammation, or calcification that drive end-stage renal disease (ESRD). This approach moves beyond bulk tissue analysis, potentially identifying precise, spatially-defined therapeutic targets to personalize management and delay the need for dialysis or transplantation.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
